The mechanism underlying bone metastasis pain in lung cancer mediated by Gm31083/miR-450b-5p/EphB1 pathway / 中国基层医药

ABSTRACT

Objective:To investigate the mechanism underlying bone metastasis pain in lung cancer mediated by Gm31083/miR-450b-5p/EphB1 pathway.Methods:Between January 2020 and December 2021, a total of 20 healthy specific pathogen-free (SPF) grade Sprague-Dawley mice were selected and randomly divided into a sham operation group and a model group using a random number table method, with 10 mice in each group. A lung cancer bone metastasis pain model was established by injecting human lung adenocarcinoma A549 cells into the femur of each mouse in the model group. The middle part of the left plantar area of the mouse was stimulated with 2 g Von Frey fine fibers, and the mouse's foot retraction response was observed for 5-6 seconds. The pain threshold of each mouse was measured using a hot plate instrument. The expression of miR-450b-5p was determined by real-time fluorescence quantitative polymerase chain reaction. The expression of Gm31083 and EphB1 proteins was determined by western blot assay.Results:The foot contraction response rate in the model group was (31.98 ± 6.36)%, which was significantly higher than (22.78 ± 4.54)% in the sham operation group ( t = -3.72, P < 0.05). The heat pain threshold in the model group was (8.18 ± 2.53) seconds, which was significantly lower than (15.42 ± 3.97) seconds in the sham operation group ( t = 4.86, P < 0.001). The relative expression level of miR-450b-5p in the model group was (1.62 ± 0.29), which was significantly higher than (1.00 ± 0.04) in the sham operation group ( t = -6.70, P < 0.001). The grayscale values of Gm31083 and EphB1 proteins in the model group mice were (1.23 ± 0.21) and (2.73 ± 0.28), respectively, which were significantly higher than (0.67 ± 0.18) and (1.25 ± 0.24) in the sham operation group ( t = -6.40, -12.69, both P < 0.001). Conclusion:Gm31083/miR-450b-5p/EphB1 is highly expressed in mice suffering from bone metastasis pain after developing lung cancer, and may become a new biomarker for evaluating bone metastasis pain in lung cancer.